On October 27th and 28th, the 5th Consortium Meeting of TransBioLine took place in Barcelona, where nearly 50 Consortium members met face to face for the first time after the pandemic. The 5th Consortium Meeting [...]
During year 3, clinical studies within the TransBioLine project are progressing in the enrolment of patients to move forward in the identification of novel biomarkers that reliably indicate specific organ injury during drug development. Status [...]
The FDA has decided to Accept the DILI Work Package into the Biomarker Qualification Program. We are very happy to have DIVI, DINI, DIKI and DILI already accepted by the FDA Biomarker Qualification Program! Take [...]
From February 28th to March 1st 2019 participants from the 27 partners of the Consortium met during two full days to begin a new adventure. The meeting took place in Basel, Switzerland, in Novartis premises [...]
Innovative Medicines Initiative Launches Translational Safety Biomarker Pipeline Project […]
